Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine

This study followed healthcare personnel (HCP) who had completed a primary series of CoronaVac and then received the third and fourth doses of COVID-19 vaccine. The primary objective was to determine the seroconversion rate of neutralizing antibodies against wild-type SARS-CoV-2 and VOCs at day 28 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaiwarith, Romanee, Winichakoon, Poramed, Salee, Parichat, Sudjaritruk, Tavitiya, Wipasa, Jiraprapa, Chawansuntati, Kriangkrai, Yasri, Saowaluck, Thongwitokomarn, Harit, Krasaewes, Kawisara, Ruangsirinusorn, Sethawut, Praparattanapan, Jutarat, Solai, Nuttarika, Nuket, Khanuengnit, Boonmee, Darakorn, Chaichana, Orapin, Mueangmo, Oramai, Saheng, Jutamad, Wongjak, Worawan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643552/
https://www.ncbi.nlm.nih.gov/pubmed/37957189
http://dx.doi.org/10.1038/s41598-023-45735-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643552/
https://www.ncbi.nlm.nih.gov/pubmed/37957189
http://dx.doi.org/10.1038/s41598-023-45735-7

Ejemplares similares